[613] | 1 | DVBCWLL4 ;ALB/RLC LIVER, GALL BLADDER AND PANCREAS WKS TEXT - 1 ; 19 FEBRUARY 1999
|
---|
| 2 | ;;2.7;AMIE;**86**;July 22, 2004
|
---|
| 3 | ;
|
---|
| 4 | ;
|
---|
| 5 | TXT ;
|
---|
| 6 | ;;
|
---|
| 7 | ;;
|
---|
| 8 | ;;C. Physical Examination (Objective Findings):
|
---|
| 9 | ;;
|
---|
| 10 | ;;Address each of the following as appropriate, and fully describe current
|
---|
| 11 | ;;findings:
|
---|
| 12 | ;;
|
---|
| 13 | ;; 1. Abdominal Exam
|
---|
| 14 | ;;
|
---|
| 15 | ;; a. Describe any areas of tenderness and/or organomegaly, including liver
|
---|
| 16 | ;; size and whether it is tender to palpation.
|
---|
| 17 | ;; b. Presence or absence of ascites
|
---|
| 18 | ;; c. Evidence of Portal Hypertension (e.g. superficial abdominal veins,
|
---|
| 19 | ;; splenomegaly, abdominal pain)
|
---|
| 20 | ;;
|
---|
| 21 | ;; 2. General exam
|
---|
| 22 | ;;
|
---|
| 23 | ;; a. Describe all other signs of liver disease (e.g. jaundice, palmar
|
---|
| 24 | ;; erythema, spider angiomata).
|
---|
| 25 | ;; b. Evidence of Malnutrition (e.g. muscle wasting)
|
---|
| 26 | ;;
|
---|
| 27 | ;;D. Diagnostic and Clinical Tests:
|
---|
| 28 | ;;
|
---|
| 29 | ;; 1. For esophageal varices, X-ray, endoscopy, etc.
|
---|
| 30 | ;;
|
---|
| 31 | ;; 2. For gall bladder disease, X-ray or other objective confirmation.
|
---|
| 32 | ;;
|
---|
| 33 | ;; 3. For liver disease:
|
---|
| 34 | ;;
|
---|
| 35 | ;; a. serologic tests for hepatitis as appropriate (e.g. HbsAg,
|
---|
| 36 | ;; anti-HCV, anti-HBc, ferritin, alpha-fetoprotein); liver imaging
|
---|
| 37 | ;; as appropriate, (e.g. ultrasound or abdominal CT scan), biopsy
|
---|
| 38 | ;; report (when available).
|
---|
| 39 | ;;
|
---|
| 40 | ;; b. Viral hepatitis (including Hepatitis C): Name the specific type
|
---|
| 41 | ;; (A, B, C, or other). For hepatitis B and / or hepatitis C,
|
---|
| 42 | ;; provide an opinion as to which risk factor is the most likely
|
---|
| 43 | ;; cause, and whether these risk factors were present during the
|
---|
| 44 | ;; veteran's time in the military. Please support your opinion by
|
---|
| 45 | ;; discussing all risk factors in the individual and your rationale
|
---|
| 46 | ;; for your opinion. If you cannot determine which risk factor is
|
---|
| 47 | ;; the likely cause, state that there is no risk factor that is
|
---|
| 48 | ;; more likely than another to be the cause, and explain.
|
---|
| 49 | ;;
|
---|
| 50 | ;; c. Hepatitis C: Please note that Hepatitis C generally does not
|
---|
| 51 | ;; produce clinically evident hepatitis at the time of infection.
|
---|
| 52 | ;; Please provide results of serologic (anti-HCV antibody) and
|
---|
| 53 | ;; viral (HCV RNA) testing for hepatitis C. The anti-HCV assay
|
---|
| 54 | ;; confirms exposure to hepatitis C but does not differentiate
|
---|
| 55 | ;; between chronic, acute, or resolved infection. False positive
|
---|
| 56 | ;; and false negative results occur, but rarely. A positive
|
---|
| 57 | ;; qualitative or quantitative HCV RNA assay indicates current
|
---|
| 58 | ;; hepatitis C infection. A negative qualitative HCV RNA assay
|
---|
| 59 | ;; indicates that the individual does not have active, chronic
|
---|
| 60 | ;; hepatitis C. The recombinant immunoblot assay (RIBA) is a
|
---|
| 61 | ;; confirmatory serologic test that establishes the diagnosis of
|
---|
| 62 | ;; past (resolved) infection if the anti-HCV is positive but the
|
---|
| 63 | ;; HCV RNA assay is negative. (Reference: Under Secretary for
|
---|
| 64 | ;; Health's Information Letter 10-2002-019 "Diagnostic Testing
|
---|
| 65 | ;; for Hepatitis C"
|
---|
| 66 | ;; http://vaww.va.gov/publ/direc/health/infolet/10200219.pdf
|
---|
| 67 | ;;
|
---|
| 68 | ;;The following are established risk factors for acquisition of hepatitis C
|
---|
| 69 | ;;infection:
|
---|
| 70 | ;;
|
---|
| 71 | ;; -Blood transfusion before 1992
|
---|
| 72 | ;; -Past or present intravenous drug use
|
---|
| 73 | ;; -Blood exposure of skin or mucous membranes including accidental needle
|
---|
| 74 | ;; punctures
|
---|
| 75 | ;; -Sexual transmission (though most studies have failed to identify sexual
|
---|
| 76 | ;; transmission of this agent). Sexual transmission appears to be confined
|
---|
| 77 | ;; to such subgroups as persons with multiple sexual partners and sexually
|
---|
| 78 | ;; transmitted diseases.
|
---|
| 79 | ;; -History of hemodialysis
|
---|
| 80 | ;; -Tattoo or repeated body piercing
|
---|
| 81 | ;; -History of intranasal cocaine use
|
---|
| 82 | ;;
|
---|
| 83 | ;;See Harrison's Principles of Internal Medicine, 15th edition, The McGraw Hill
|
---|
| 84 | ;;Companies, Inc., page 1709, 1729-1730.
|
---|
| 85 | ;;
|
---|
| 86 | ;;Please consider the veteran's potential for skin and mucous membrane exposure
|
---|
| 87 | ;;to blood, especially where the veteran was a military corpsman, a medical
|
---|
| 88 | ;;worker, or a combat veteran.
|
---|
| 89 | ;;
|
---|
| 90 | ;; (d) Cirrhosis, chronic hepatitis, liver malignancy, or other chronic liver
|
---|
| 91 | ;; disease: State the most likely etiology. Address the relationship of
|
---|
| 92 | ;; the disease to active service, including any hepatitis that occurred
|
---|
| 93 | ;; in service.
|
---|
| 94 | ;;
|
---|
| 95 | ;; 5.Include results of all diagnostic and clinical tests conducted in the
|
---|
| 96 | ;; examination report.
|
---|
| 97 | ;;
|
---|
| 98 | ;;E. Diagnosis:
|
---|
| 99 | ;;
|
---|
| 100 | ;;
|
---|
| 101 | ;;Signature: Date:
|
---|
| 102 | ;;END
|
---|